YOD1 and head and neck squamous cell carcinoma: In this study, the experimental results showed that YOD1 modified TRIM33 through deubiquitination, maintaining the stability of TRIM33 and thus inhibiting the proliferation and metastasis of HNSCC cells by inhibiting the activation of ERK and β-catenin signaling pathways.